Experimental drug offers hope for advanced cancers with no other options

NCT ID NCT07021066

Summary

This early-stage trial is testing a new drug called BL-M05D1 in people with advanced cancers that have spread and stopped responding to standard treatments. The study will enroll 120 patients with specific cancers like stomach, pancreatic, and esophageal cancer to determine the safest dose and see if the drug shows any effectiveness. This is the first time this experimental treatment is being given to humans, so the main focus is on safety and how the body processes the drug.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Baylor Scott and White Medical Center- Temple Clinic

    NOT_YET_RECRUITING

    Temple, Texas, 76504, United States

    Contact Email: •••••@•••••

    Contact

  • Hackensack University Medical Center

    NOT_YET_RECRUITING

    Hackensack, New Jersey, 07601, United States

    Contact

    Contact Email: •••••@•••••

  • HonorHealth

    NOT_YET_RECRUITING

    Scottsdale, Arizona, 85266, United States

    Contact Email: •••••@•••••

    Contact

  • Karmanos Cancer Institute

    NOT_YET_RECRUITING

    Detroit, Michigan, 48201, United States

    Contact Email: •••••@•••••

    Contact

  • MD Anderson

    NOT_YET_RECRUITING

    Houston, Texas, 77030, United States

    Contact

    Contact Email: •••••@•••••

  • Mayo Clinic Cancer Center- Phoenix

    NOT_YET_RECRUITING

    Phoenix, Arizona, 85054, United States

    Contact

    Contact Email: •••••@•••••

  • Memorial Sloan Kettering Cancer Center

    NOT_YET_RECRUITING

    New York, New York, 10065, United States

    Contact

    Contact Email: •••••@•••••

  • NEXT Oncology San Antonio

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact

    Contact Email: •••••@•••••

  • NEXT Oncology- Austin

    RECRUITING

    Austin, Texas, 78758, United States

    Contact Email: •••••@•••••

    Contact

  • NEXT Oncology- Dallas

    RECRUITING

    Dallas, Texas, 75039, United States

    Contact

    Contact Email: •••••@•••••

  • Ochsner Medical Center

    NOT_YET_RECRUITING

    New Orleans, Louisiana, 70121, United States

    Contact Email: •••••@•••••

    Contact

  • START Center for Care Center- San Antonio

    NOT_YET_RECRUITING

    San Antonio, Texas, 78229, United States

    Contact

    Contact Email: •••••@•••••

  • Sarah Cannon Research Institute - Oncology Partners

    RECRUITING

    Nashville, Tennessee, 37203, United States

    Contact

    Contact Email: •••••@•••••

  • University of Colorado Health

    NOT_YET_RECRUITING

    Aurora, Colorado, 80045, United States

    Contact Email: •••••@•••••

    Contact

  • University of Michigan

    NOT_YET_RECRUITING

    Ann Arbor, Michigan, 48109, United States

    Contact Email: •••••@•••••

    Contact

  • Vanderbilt-Ingram Cancer Center

    NOT_YET_RECRUITING

    Nashville, Tennessee, 37232, United States

    Contact

    Contact Email: •••••@•••••

  • Yale Cancer Center

    NOT_YET_RECRUITING

    New Haven, Connecticut, 06510, United States

    Contact

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.